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Abstract We measured quantitatively the mRNA levels of 
intracellular and secretory forms of gelsolin, an actin-modulating 
protein, in human tissues from subjects of different ages. The 
intracellular gelsolin mRNA constituted the major type of 
gelsolin steady-state mRNA in all tissues analyzed. Both forms 
of gelsolin were expressed in most adult tissues, with particularly 
high mRNA levels in all types of muscle and interestingly in skin. 
Between the adult and infantile tissues the most striking 
difference in expression levels was found in liver, as the adult 
liver contained only a subtle amount of gelsolin mRNA. Skin and 
muscle samples from patients with gelsolin-related amyloidosis 
(FAF), with significantly increased concentrations of serum 
gelsolin, did not reveal an increased expression of the gene, and 
both mutant and wild-type alleles were expressed in equal 
amounts. The high level of expression of the gelsolin gene in the 
skin in general could locally contribute to the characteristic skin 
amyloidosis in FAF patients. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Gelsolin is a protein of higher eukaryotes that was first 
identified as a factor mediating the change of a gel-like cyto-
plasmic extract to a soluble phase in the presence of calcium 
[1]. The gel-sol transition is the consequence of the severing of 
actin filaments, but gelsolin is also capable of capping the 
barbed ends of actin filaments and, under appropriate condi-
tions, of promoting actin polymerization (reviewed in [2]). 
Gelsolin occurs in two forms, intracellular (cytoplasmic) and 
secreted (plasma), which are encoded by a single gene located 
on chromosome 9 [3-5]. The intracellular gelsolin participates 
in the regulation of the cellular actin network, and is required 
in rapid stress responses involving locomotion of cells, such as 
responses to hemostasis or inflammation [6,7]. Recent studies 
have suggested an additional role of the intracellular gelsolin 
in signal transduction through its binding to phosphatidylino-
sitol 4,5-bisphosphate [8,9]. The physiological significance of 
the secretory form of gelsolin is not well known, but it has 
been suggested to depolymerize and sequester actin that has 
been released during cellular damage [10]. 
Corresponding author. Fax: (358) (9) 4744480. 
E-mail: tiina.paunio@ktl.fi 
Abbreviations: GSN, gelsolin; S-GSN, secretory gelsolin; Tot-GSN, 
total gelsolin; PCR, polymerase chain reaction; RT, reverse transcrip-
tion ; FAF, familial amyloidosis of the Finnish type 
After their initial discovery, the two forms of gelsolin have 
been shown to be synthesized in most types of cells and tissues 
and, interestingly, variations in the level of expression of the 
gelsolin gene have been observed both during cell differentia-
tion and in carcinogenesis [11-15]. However, despite numer-
ous studies on the synthesis of gelsolin in cells, the expression 
pattern of the gelsolin gene in different human tissues has not 
been systematically studied, most previous reports concentrat-
ing mainly on animal tissues or only on a few types of human 
tissues or cells [16-19]. 
A mutation in the gelsolin gene results in an autosomal 
dominantly inherited amyloid disease (familial amyloidosis, 
Finnish type or FAF) histologically characterized by accumu-
lation of gelsolin fragments as amyloid deposits in most tis-
sues [20-22]. We have previously demonstrated that FAF pa-
tients have significantly elevated levels of gelsolin in their 
serum [23]. The underlying mechanism of this feature, which 
might have a role in the disease pathogenesis by enhancing the 
amyloid formation, could involve increased compensatory 
synthesis of the possibly functionally impaired mutant gelsolin 
in patients [24]. 
To study the expression levels of gelsolin mRNA in tissues 
of healthy individuals of varying age as well as in those of 
FAF patients, we developed a method for quantification of 
the gelsolin mRNA. The method is based on reverse tran-
scription (RT) of the sample mRNAs followed by the poly-
merase chain reaction (PCR) together with an internal quan-
tification standard that differs only by a single nucleotide from 
the analyzed mRNA region. Furthermore, by separately de-
termining the levels of the unique 5' sequence of the secretory 
gelsolin (S-GSN) mRNA and of the 3' region shared by the 
two forms of gelsolin (Tot-GSN) mRNA, we were able to 
calculate the ratios of the mRNA species encoding the secre-
tory and intracellular forms of gelsolin. 
2. Materials and methods 
2.1. Tissue samples 
We studied tissues from six healthy adults (A1-A6), a newborn 
(NB1), a fetus of 26 weeks (Fl) and five FAF patients (P1-P5) (Table 
1). All the FAF patients had been previously shown to carry the 
G654A mutation of the gelsolin gene [25], and they all showed typical 
signs of corneal lattice dystrophy as well as cranial, especially facial, 
neuropathy [26]. Tissue specimens from all of them had been histo-
pathologically demonstrated to contain amyloid [26]. 
The tissue specimens from the individuals A1-A5 and P1-P5 were 
frozen in liquid nitrogen and stored at —70°C. The autopsy samples 
from subjects A6, NB1 and NB2 were taken within 24 h of death, 
frozen and stored at —70°C. Total cellular RNA was extracted using 
the RNA-zol procedure (Cinna/Biotech Laboratories International, 
Texas, USA). The concentration of the extracted RNA was immedi-
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ately determined by UV absorption at 260 nm, after which the RNA 
samples were stored at —70°C in 70% ethanol. Possible DNA con-
tamination in the RNA samples was excluded by the absence of prod-
uct when the samples were subjected to PCR without a reverse tran-
scription step. The quality of the RNA specimen was assessed by 
performing successful RT-PCR amplifications of two control genes, 
aspartylglucosaminidase and fibrillin, that are routinely analyzed in 
our laboratory [27,28]. 
2.2. Quantification standards for PCR 
Gelsolin cDNA cloned into M13mpl8 served as a standard with the 
normal sequence [29]. A standard with a mutant sequence was pre-
pared from this cDNA clone by site-specific mutagenesis of the nu-
cleotides at positions 128 (G-»A) and 654 (G-»T) of the gelsolin 
cDNA. The replicative form of the M13 clones was purified by the 
CsCl2 method with two subsequent gradient centrifugations. The 
quality of the DNA was assessed by agarose gel electrophoresis and 
the DNA concentration was determined by UV absorption at 260 nm. 
In calculating the number of molecules of standard, the fact that both 
strands of the standard DNA will serve as a template in the PCR 
amplification, while the target sequence is single stranded, was taken 
into account. Before use, the gelsolin insert was excised from the 
vector using EcoRl and the digested sample was stored in aliquots 
at -70°C. 
Standard curves for the quantitative analysis were established by 
mixing the normal and mutant standard sequences in known ratios, 
followed by PCR and detection of the nucleotide at positions 128 and 
654 by solid-phase minisequencing (Figs. 1 and 2) [27,30]. For deter-
mining the relative levels of normal and mutant GSN-mRNA in FAF 
patients, mixtures of genomic DNA from a FAF patient and normal 
individual were used for preparation of a standard curve [25,28]. 
2.3. Reverse transcription and PCR 
Table 2 gives the sequences of the primers used in the RT and PCR 
reactions. 200-500 ng of total cellular RNA was reverse transcribed 
using 25 pmol of the primer GSN-764 or GSN-223, 20 nmol of each 
dNTP, 20 U of RNAsin (Promega Biotech, Helsinki, Finland) and 25 
U of AMV reverse transcriptase (Promega) in 20 ul of buffer contain-
ing 50 mM Tris-HCl, pH 8.4, 40 mM KC12, 5 mM MgCl2 and 2 mM 
DTT. Four or 9 ill of the RT mixture was subjected to PCR ampli-
fication together with 104-106 molecules of the mutant standard se-
quence. The amount of the mutant standard sequence had previously 
been titrated to give a ratio of 0.1-10 in the minisequencing assay. 
The PCR reaction mixtures contained 20 pmol of the biotinylated 
primer GSN-B543 and 100 pmol of the primer GSN-707, or 20 
pmol of the biotinylated primer GSN-B16 and 100 pmol of the primer 
GSN-162, 20 nmol of each dNTP and 2.5 U of DNA polymerase 
(Dynazyme II, Finnzymes, Helsinki, Finland) in 100 ul buffer con-
taining 40 mM Tris-HCl, pH 8.8, 15 mM (NH4)2S04, 0.01% gelatin, 
0.1% Triton X-100 and 1.5 mM MgCl2. For amplification with the 
primers GSN-B16 and GSN-162, 5% (v/v) of DMSO was included in 
the buffer and the DNA polymerase was added to the PCR reactions 
employing a 'hot start' procedure. The amplification was performed at 
95°C for 1 min, at 59-60°C for 1 min and at 72°C for 1 min for 30-40 
cycles. 
2.4. Solid-phase minisequencing 
To allow for duplicate assays of both sequences in the sample 
mixture, four 10 ul aliquots of each PCR product were captured in 
streptavidin-coated microtitration wells (Combiplate 8, Labsystems, 
Helsinki, Finland), the wells were washed and the DNA was dena-
tured as described in detail previously [25,31]. The minisequencing 
reaction mixture contained 10 pmol of the primer GSN-674 (Table 
2) or primer GSN-148 (Table 2), 3 pmol of [3H]dNTP ([3H]dATP, 
sp.ac 75 Ci/mmol; [3H]dCTP, sp.ac. 64 Ci/mmol; [3H]dTTP, sp.ac. 
121 Ci/mmol, Amersham, UK) and 0.05 U of DNA polymerase in 50 
Hi of its buffer. The minisequencing reactions were carried out for 10 
min at 55°C. After washing and denaturation, the incorporated radio-
activity was measured in a liquid scintillation counter. The final quan-
titative result was obtained by comparing the ratio between the in-
corporated [3H]dNTPs and a standard curve (Figs. 1 and 2). 
2.5. Immunochemical analyses of gelsolin 
The gelsolin of the serum samples of individuals P l -5 was quanti-
fied using a radioimmunoassay described in [23], For Western blot 
analysis of the tissue specimens, 20 ug of tissue (skin, heart, intestine, 
kidney and brain) kept on dry ice were crushed and dissolved in 800 
ul of 0.5% Triton X-100 in phosphate buffered saline containing 
EDTA (1.2 mg/ml) and PMSF (35 mg/ml) as protease inhibitors. 
The samples were freeze-thawed twice, and the supernatant was 
used in the further assays. The protein concentration of the tissue 
samples was determined using a protein detection assay (Bio-Rad, 
Hercules, CA, USA) [32], 20 ug of protein solubilized from the tissue 
samples was subjected to 10% SDS-PAGE, electroblotting and immu-
nodetection using monoclonal antibody recognizing carboxy-terminal 
epitope of gelsolin, as described previously [23]. 
3. Results 
We applied a quantitative method based on R T - P C R and 
solid-phase minisequencing to determine the levels of gelsolin 
m R N A in tissues derived from normal adults, a fetus, a new-
born and patients with F A F . Because a single gene encodes 
Table 1 
Subjects and analyzed tissues 
Subjects Age Tissue Health status 
Normal adults 
Al (female) 
A2 (male) 
A3 (female) 
A4 (male) 
A5 (male) 
A6 (female) 
Fetus/newborn 
Fl 
NB1 
FAF patients 
PI 
P2 
P3 
P4 
P5 
30 years 
30 years 
37 years 
54 years 
56 years 
83 years 
26 weeks" 
41 weeksa 
43 years 
47 years 
54 years 
55 years 
75 years 
Placenta 
Skin 
Muscle 
Muscle, skin 
Skin (healthy area) 
Muscle, heart, liver, kidney, spleen, brain 
Muscle, heart, large intestine, liver, kidney, brain, 
peripheral nerve 
Muscle, heart, small intestine, liver, kidney, brain 
Muscle, skin 
Muscle, skin 
Skin 
Muscle, skin 
Skin 
Healthy 
Healthy 
Post polio syndrome 
Healthy 
Carcinoma basocellulare 
Accidental death 
Idiopathic respiratory distress syndrome 
(2nd of twins) 
Hypoglycemia, metabolic acidosis 
Familial amyloidosis, Finnish 
Familial amyloidosis, Finnish 
Familial amyloidosis, Finnish 
Familial amyloidosis, Finnish 
Familial amyloidosis, Finnish 
aFor Fl and NB1, the gestational age is given. 
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both the secretory and the intracellular forms of gelsolin [4], 
we quantified separately the unique 5' end of the secretory 
form of gelsolin mRNA and the RNA region shared by the 
two gelsolin forms. A known amount of an internal standard 
sequence differing from the normal sequence at nucleotide 
positions 128 and 654 of the gelsolin gene is added to the 
cDNA sample prior to the PCR amplification in both assays 
(Fig. 1). As the sequences originating from the mRNA sample 
and from the quantification standard differ only by a single 
nucleotide, they are amplified with equal efficiency and their 
relative amounts can be accurately determined in the mini-
sequencing reaction [27]. 
3.1. Tissue distribution of total gelsolin mRNA 
Gelsolin mRNA was present in all analyzed adult tissues 
(Fig. 3A and Table 3). Particularly high transcript levels were 
measured in skin, skeletal and cardiac muscle as well as in 
placenta (range of mean values 1.1-2.5 X107 of Tot-GSN 
mRNA molecules per |xg of total RNA). The interindividual 
differences in the skin samples were high, more than 10-fold, 
while only 2-fold differences were observed in the muscle sam-
ples. Intermediate mRNA levels were observed in brain, kid-
ney and spleen (2.5^1.9 X 106 molecules per (j.g of total RNA), 
while only a subtle amount of gelsolin mRNA (2.4 X 105 mol-
ecules per (ig total RNA) was detectable in liver. 
S-GSN mRNA: 
S-GSN —G— 
(128) 
Tot-GSN mRNA: 
G # IC-GSN-
(654) 
-# S-GSN 
RNA Quantification standard 
(mutant sequence) 
RNA 
i 
cDNA 
RT 
PCR 
B EEJ--► B ^ s ~ * 
—A — 
— T -
(128) 
—T — 
—A— 
(654) 
Solid-phase 
minisequencing 
Comparison 
with standard 
curve 
Amount of Tot-GSN mRNA in sample 
Fig. 1. Strategy for quantitative analysis of S-GSN and Tot-GSN mRNAs by RT-PCR and solid-phase minisequencing. The figure illustrates 
the positions of the PCR primers and the nucleotides with which the S-GSN (left) and Tot-GSN (IC-GSN and S-GSN) (right) mRNAs were 
quantified separately. The sequences are shown schematically, and the nt numbering is not in scale. In IC-GSN, the transcribed region common 
with S-GSN begins at nt 159. After the RT reaction a known amount of quantification standard is added to the sample and the mixed sample 
is amplified by PCR using primers flanking nt positions 128 and 654, respectively. The PCR product is captured on a solid support by the bio-
tin-streptavidin interaction and denatured. In the minisequencing reaction a specific primer annealing adjacent to the analyzed nucleotide posi-
tion (128 or 654) is extended by a DNA polymerase with a single labeled nucleoside triphosphate. The incorporated label is measured and the 
result is obtained by comparing the ratio between the incorporated labels and the quantification standard curve. S-GSN, secretory gelsolin; IC-
GSN, intracellular gelsolin; Tot-GSN, total gelsolin. 
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The steady-state mRNA level of the gelsolin gene differed in 
the tissues of the 26-week fetus (Fl) and the newborn (NB1) 
when compared to adult tissues (Fig. 3B). The amount of 
gelsolin mRNA in the liver and heart from Fl and NB1 
was 32 and 3 times higher than in the adults, respectively, 
while a low level of gelsolin mRNA compared to that of 
adults was observed in the brain tissue of Fl and NB1 and 
in the peripheral nerve from Fl (range 9.4—9.5 X 105 molecules 
per ug of total RNA). Fl and NB1 gelsolin mRNA levels 
differed most from each other in the cardiac muscle (4-fold) 
and intestine (4-fold), the mRNA level of Fl being higher in 
the intestine and that of NB1 being higher in the heart tissue. 
Thus, no striking differences were found between these two 
subjects representing different developmental stages. 
3.2. Levels of mRNA encoding secretory gelsolin 
After determining the level of total gelsolin mRNA in var-
ious tissues, we determined separately the level of S-GSN 
mRNA in skeletal and cardiac muscle, spleen, kidney and 
brain of the adult A6 and in the skin of one of the patients, 
P3. The amount of mRNA encoding S-GSN was between 13 
and 23% of the Tot-GSN mRNA. The highest levels of S-
GSN mRNA were measured in heart and skin (2.7 X106 
and 2.2 X 106 molecules per ug of total RNA), and the largest 
proportion of S-GSN mRNA was determined in the heart 
(23%). The mRNA level in the brain was below 5.0 X 105 
molecules per (ig of total RNA. We confirmed these unexpect-
edly low levels of mRNA encoding S-GSN [16] by conven-
tional dot blot hybridization analysis of RNA from the 
muscle sample using PCR products obtained from regions 
defining the S-GSN or Tot-GSN DNA as probes. In this 
analysis, the hybridization signals obtained from S-GSN 
mRNA were less than one third of those obtained for the 
Tot-GSN mRNA, thereby being in accordance with the result 
obtained using the minisequencing method. 
3.3. Gelsolin mRNA and serum gelsolin levels in FAF 
In order to study the possible relationship between the pre-
viously shown elevated gelsolin levels in the serum of FAF 
patients and the expression of the gelsolin gene [23], we de-
termined the mRNA levels in skin and/or muscle samples, and 
the serum gelsolin concentration of patients P1-P5. The mean 
values of Tot-GSN mRNA in skin and muscle from the pa-
tients (1.1 X 107 and 1.5 X107 molecules per ug of total RNA) 
were 61%> and 136% of those of the controls (Table 4 and Fig. 
cpm 
'cpm 
cpm 
'cpm 
1 10 0.1 1 
Ratio between mutant and normal sequence 
10 
Fig. 2. Solid-phase minisequencing standard curves for quantifica-
tion of S-GSN mRNA (A) and of Tot-GSN mRNA (B). The ratio 
between the cpm values obtained from the incorporated nucleotides 
at position 654 or 128 is plotted as a function of the ratio between 
the sequences in the original mixture. The nucleotides of the non-
coding strand of the GSN gene were analyzed. The obtained ratios 
depend on the specific activities of the [3H]dNTPs used, and on the 
fact that two [3H]dCTPs will be incorporated in the allele with 
Gi28-
3). The levels of serum gelsolin ranged from 160 to 270 |xg/ml, 
and did not correlate with the mRNA levels in these tissues 
with highest steady-state mRNA amounts. Consequently, the 
elevated serum gelsolin levels of FAF patients [23] are not 
caused by an increased steady-state level of gelsolin mRNA. 
The relative levels of mRNA encoded by the normal allele 
(with nucleotide G at position 654) and the mutant allele 
(A654) were obtained by quantitative minisequencing analysis 
of patient skin and muscle samples without the addition of the 
standard sequence. The relative amounts of the two mRNAs 
ranged from 0.93 to 1.1 (mean value 1.0 ±0.058). Thus, 
although the total gelsolin mRNA levels showed large inter-
individual differences, especially in skin, the normal and the 
FAF-associated alleles of the gelsolin gene were present in 
equal ratios (Table 4). 
3.4. Gelsolin in normal and FAF tissues 
Finally, we analyzed gelsolin extracted from the tissue 
specimens of individuals A5, NB1, Fl and P3 that had been 
subjected to GSN mRNA quantification, by Western blot 
analysis using gelsolin-specific antibodies. We found a rela-
tively good concordance between the gelsolin mRNA levels 
and the amount of the gelsolin polypeptides seen in the im-
Table 2 
RT and PCR primers 
Primer Use Sequence and position as nt number of the gelsolin cDNA 
Tot-GSN mRNA* 
GSN-764 
GSN-B543b 
GSN-707 
GSN-674 
S-GSN mRNA" 
GSN-223 
GSN-B16b 
GSN-162 
GSN-148 
RT 
PCR 
PCR 
minisequencing 
RT 
PCR 
PCR 
minisequencing 
5'-GTTGTCCCGGATGCCCTT (764-747) 
5'-AAGCACGTGGTACCCAAC (543-560) 
5'-GTTGGAACCACACCACTG (707-690) 
5'-CAGGTCCAGGATGAAGCAGT (674-655) 
5'-ATCTGCAGGCCAGGCTCCTT (223-204) 
5'-TGGCTCCGCACCGCCCCGCGCC (16-37) 
5'-TGGGCCGCGCCTCGGGCACCCG (162-141) 
5'-GGCACCCGCCCCTGGGGCGC (148-129) 
aThe primers were synthesized on an Applied Biosystems 392 DNA synthesizer and they were designed according to the published sequence of the 
GSN gene [4]. 
bThe primers GSN-B543 and GSN-B16 were biotinylated at their 5' end. 
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Fig. 3. Levels of Tot-GSN mRNA determined in tissue samples 
from normal adults (A) and from a fetus and a newborn (B). The 
number of samples analyzed is shown in parentheses. When tissues 
from more than one individual were analyzed, the mean values and 
variation ranges are given. 
munoblots of most tissue samples (Fig. 4). Two main gelsolin 
species of 80 and 83 kDa in size, corresponding to the intra-
cellular and secretory forms of the protein respectively, were 
detected using an anti-gelsolin antibody that recognizes the 
carboxy-terminal part of the protein (Fig. 4). 
4. Discussion 
We developed a method for quantifying gelsolin mRNA 
and applied it to analyze the steady-state mRNA levels in 
various tissue samples from healthy adults, from a fetus and 
a newborn, as well as from patients with gelsolin-related amy-
loidosis (FAF). Our PCR-based technique enabled us to de-
tect gelsolin mRNA more accurately and sensitively than 
would be possible by more conventional methods, such as 
blot hybridizations or nuclease protection assays. The prob-
lems associated with quantitative PCR analysis were avoided 
by addition of an internal quantification standard that differs 
from the GSN sequence by a single nucleotide to the samples 
before PCR [27,33]. Ideally a quantification standard for RT-
PCR should be added to the sample before the RNA extrac-
tion step to control for possible degradation of the GSN 
mRNA during the processing of the tissue samples and for 
the reverse transcription step. The efficiency of the RT reac-
tion has, however, been shown to be close to 100%, and in-
dependent of the RNA concentration in the sample [34], and 
careful precautions to avoid RNA degradation were taken in 
our study. However, the measured GSN mRNA amounts 
reflect their levels at the moment of sampling, and conclusions 
about the implication of the mRNA levels on the actual GSN 
synthesis are indirect since, even within a given organism, the 
half-lives of different mRNA species may vary considerably 
[35]. The half-life of neither the secretory nor the intracellular 
type of gelsolin is known, but we were able to demonstrate a 
relatively good correlation between the mRNA levels and the 
amount of polypeptide in immunoblots of the same tissue 
samples. 
This is to our knowledge the first report in which several 
human tissues have been systematically compared for their 
content of gelsolin mRNA. Interestingly, we found that the 
epidermal and dermal layers of the skin contain high levels of 
the steady-state mRNA of both the intracellular and secretory 
forms of gelsolin, although there were strikingly great differ-
ences between the study samples. These results suggest that 
gelsolin has an important physiological role in skin, possibly 
related to some adaptive mechanisms, such as wound healing, 
where locomotion of the fibroblasts and epithelial cells as well 
as destruction of the extracellular debris containing e.g. actin 
is needed. The requirement for gelsolin in wound healing has 
also been suggested in a recent study, in which gelsolin knock-
out fibroblasts were shown to migrate more slowly than nor-
mal fibroblasts in tissue culture [36]. Our finding of high levels 
of intracellular gelsolin mRNA in different types of muscle, in 
which the physiological target of gelsolin (actin) is abundant, 
was not surprising, and this finding agrees with previous re-
ports (see for example [16-18]). Although actin is considered 
to have an important role in the cytoskeletal plasticity of the 
neurons [37], we found only intermediate levels of the total 
gelsolin mRNA in adult brain, and, moreover, in the newborn 
and fetal brains, gelsolin mRNA was scarce as compared to 
the other tissues. Therefore the present results are slightly 
discordant with those obtained by analyzing murine cerebrum 
Table 3 
Example of quantification of Tot-GSN mRNA in tissue samples from individual A6 
Tissue Amount of standard Acpmb Ccpmb Ratio Ratio 
added (No. of molecules Acpm Mutant sequence 
Ccpm Normal sequence0 
Amount of Tot-GSN mRNA 
(No. of molecules per ug of 
Tot-RNA)d 
Heart 
Kidney 
Brain 
Spleen 
Liver 
Skeletal muscle 
1.4X106 
2.7 XlO6 
6.8 X105 
6.8 XlO5 
2.7 XlO5 
2.7 XlO6 
8.2 XlO5 
8.2 XlO5 
6.8 XlO4 
2.7 XlO5 
1.4X106 
1370 
2414 
2460 
2620 
523 
3090 
4320 
3060 
1450 
3270 
1502 
3410 
2591 
3320 
3270 
2620 
1420 
2560 
2330 
1260 
940 
4340 
0.4 
0.93 
0.74 
0.80 
0.20 
2.2 
1.7 
1.3 
1.2 
3.5 
0.35 
0.92 
2.2 
1.7 
1.9 
0.44 
5.6 
4.4 
3.3 
2.8 
9.2 
0.80 
1.5X107 
1.2 XlO7 
4.0 XlO6 
3.6 XlO6 
6.1 XlO6 
4.8 XlO6 
1.9 XlO6 
2.5 XlO6 
2.4 X106 
2.9 XlO5 
1.8X107 
a500 ng of Tot-RNA was applied to the RT reaction and one fifth of the RT reaction mixture was subjected to the PCR amplification together with 
the standard sequence. 
bMean values of duplicates. 
The ratio between amounts of the standard sequence and the GSN sequence of the sample was obtained from the standard curve in Fig. IB. 
dThe amount of Tot-GSN mRNA in the sample is calculated from the mutant/normal ratio based on the known amount of added standard. 
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Table 4 
Expression levels of the normal and mutant gelsohn alleles in FAF patients 
Tissue Muscle Skin 
Patient 
PI 
P2 
P3 
P4 
P5 
Tot-GSN mRNAa 
1.6 XlO7 
2.1 X107 
ND b 
7.2 XlO6 
ND 
mRNA ratio 
Normal 
Mutant 
1.1 
0.97 
1.1 
Tot-GSN mRNAa 
1.8 XlO7 
2.6 XlO6 
3.2 XlO7 
1.7 XlO6 
1.5X106 
mRNA ratio 
Normal 
Mutant 
0.93 
1.0 
1.0 
0.94 
1.1 
aIn quantification of the amount of Tot-GSN mRNA in patients' tissues, the presence of transcripts from two gelsohn alleles with G654 and A654, 
respectively, was taken into account. 
The results are given as molecules per |xg of total RNA. 
bND=not determined. 
or cerebellum, where maximal expression of gelsolin was 
found during active myelinogenesis in the oligodendrocytes 
(20-30 day old mice), after which the protein levels decreased 
[19,38]. 
We observed that the intracellular gelsolin constitutes the 
major form of gelsolin synthesized in all the analyzed tissues. 
Since detectable amounts of S-GSN mRNA could, however, 
be found in the majority of the tissues, the relatively high 
abundance of gelsolin in serum (100^-00 |J.g/ml) [23,39] seems 
to result from the combined production of the protein by cells 
in various organs. In this regard, the net influence of the skin 
and skeletal muscle, comprising 5 and 43% of the body 
weight, respectively, and relatively high S-GSN mRNA levels, 
is of the great importance. Our results disagree with an earlier 
report, in which up to 100% of tissue gelsolin mRNA was 
found to be of the secretory form, as measured by the nucle-
ase protection assay [16]. These discrepant results could be 
explained by methodological factors of that study, in which 
a probe was used that hybridizes to S-GSN mRNA by its 
whole length, but only partially to the mRNA encoding intra-
cellular gelsolin. Moreover, experiments with rabbit tissues 
showed that less than half (0-50%) of the newly synthesized 
gelsolin was secreted into the culture medium, e.g. represent-
ing the secretory form of gelsolin [16]. 
FAF is the only inherited disease that has so far been linked 
^ ^ # 
/ 
S ^ 
106 — 
80 -
Tot-GSN 
mRNA: 1.6 1.3 4.7 
10 7 molec/ 
0.92 0.82 0.07 0.12 (igtot-RNA 
Fig. 4. Western blot analysis of gelsolin in normal and FAF tissues. 
The protein samples from individuals A5 (skin), Fl (heart, large in-
testine, kidney) and NB1 (heart and brain) were analyzed. The cor-
responding values for Tot-GSN mRNA for the studied samples are 
given (X 107 molecules/ug of Tot-RNA). 
to gelsolin. The FAF mutation at nt position 654 of the gene, 
resulting in the change of an amino acid at position 187, leads 
to alternative cleavage of the mutant gelsolin in the secretory 
pathway of the cells [29]. This results in the secretion of an 
amino-terminally truncated fragment of gelsolin, and eventu-
ally in the accumulation of gelsolin peptides as amyloid in 
patients' tissues, in particular in the cornea, skin and nerves 
as well as skeletal and cardiac muscles [20,26,40-44]. Our 
present results suggest that, at least in the skin and muscle, 
where mRNA encoding for both the intracellular and secre-
tory forms of gelsolin was abundant, and, moreover, both the 
wild-type and mutant alleles were expressed in equal amounts, 
amyloid accumulation could be due to local production of 
mutant gelsolin. Although we did not specifically analyze 
adult peripheral nerves or mRNA from peripheral nerve cells, 
it is likely that the amyloid accumulation in the nerves of the 
FAF patients cannot be explained by a particularly high level 
of synthesis of mutant gelsolin in the nerves. 
We have reported previously that FAF patients have in-
creased levels of gelsolin in their serum and the levels both 
in serum and in liquor increase with age [23]. One plausible 
explanation for this feature could be that the mutant gelsolin 
would be functionally defective [24] and that gelsolin synthesis 
would therefore become up-regulated, especially upon aging 
when some unknown compensatory mechanisms would fail to 
function. We were, however, able to show here that the gel-
solin mRNA levels are not increased in the patients' tissues 
and, furthermore, do not correlate with the serum gelsolin 
levels. The present results therefore strongly suggest that the 
elevated serum gelsolin levels are not caused by increased ex-
pression of the gelsolin gene nor by increased stability of the 
transcript of the mutant GSN allele, but rather by transla-
tional or some catabolic events. 
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